Tags

Type your tag names separated by a space and hit enter

Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature.
Clin Neurol Neurosurg. 2012 May; 114(4):331-5.CN

Abstract

Neuromyelitis optica (NMO) is associated with antibodies to aquaporin-4 (termed NMO-IgG or AQP4-Ab) in 60-90% of cases. Little is known about the aetiology of NMO in NMO-IgG/AQP4-Ab negative patients. Here we report on CV2/CRMP5 antibodies in a 69-year-old male patient with NMO-IgG/AQP4-Ab negative NMO. The association of CV2/CRMP5-Ab with prostate cancer suggests a paraneoplastic aetiology of NMO in our patient. Our report strengthens the case of antibodies other than AQP4-Ab being involved in the immunopathogenesis in a subset of patients with NMO. We conclude that CV2/CRMP5-Ab should be included in the differential diagnosis of NMO, in particular if AQP4-Ab are negative and irrespective of whether a tumour is known or not. We recommend that recombinant tests, which are increasingly used because of their higher sensitivity and specificity, should always be accompanied by standard indirect immunofluorescence employing brain tissue sections in order to avoid CV2/CRMP5-Ab or other paraneoplastic antibodies being overlooked. In addition, we provide a comprehensive review of all patients with CV2/CRMP5-Ab and NMO-like disease published in the English literature so far.

Authors+Show Affiliations

Division of Molecular Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

22138095

Citation

Jarius, S, et al. "Antibodies to CV2/CRMP5 in Neuromyelitis Optica-like Disease: Case Report and Review of the Literature." Clinical Neurology and Neurosurgery, vol. 114, no. 4, 2012, pp. 331-5.
Jarius S, Wandinger KP, Borowski K, et al. Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clin Neurol Neurosurg. 2012;114(4):331-5.
Jarius, S., Wandinger, K. P., Borowski, K., Stoecker, W., & Wildemann, B. (2012). Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clinical Neurology and Neurosurgery, 114(4), 331-5. https://doi.org/10.1016/j.clineuro.2011.10.048
Jarius S, et al. Antibodies to CV2/CRMP5 in Neuromyelitis Optica-like Disease: Case Report and Review of the Literature. Clin Neurol Neurosurg. 2012;114(4):331-5. PubMed PMID: 22138095.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. AU - Jarius,S, AU - Wandinger,K P, AU - Borowski,K, AU - Stoecker,W, AU - Wildemann,B, Y1 - 2011/12/03/ PY - 2010/07/13/received PY - 2011/08/07/revised PY - 2011/10/31/accepted PY - 2011/12/6/entrez PY - 2011/12/6/pubmed PY - 2012/7/31/medline SP - 331 EP - 5 JF - Clinical neurology and neurosurgery JO - Clin Neurol Neurosurg VL - 114 IS - 4 N2 - Neuromyelitis optica (NMO) is associated with antibodies to aquaporin-4 (termed NMO-IgG or AQP4-Ab) in 60-90% of cases. Little is known about the aetiology of NMO in NMO-IgG/AQP4-Ab negative patients. Here we report on CV2/CRMP5 antibodies in a 69-year-old male patient with NMO-IgG/AQP4-Ab negative NMO. The association of CV2/CRMP5-Ab with prostate cancer suggests a paraneoplastic aetiology of NMO in our patient. Our report strengthens the case of antibodies other than AQP4-Ab being involved in the immunopathogenesis in a subset of patients with NMO. We conclude that CV2/CRMP5-Ab should be included in the differential diagnosis of NMO, in particular if AQP4-Ab are negative and irrespective of whether a tumour is known or not. We recommend that recombinant tests, which are increasingly used because of their higher sensitivity and specificity, should always be accompanied by standard indirect immunofluorescence employing brain tissue sections in order to avoid CV2/CRMP5-Ab or other paraneoplastic antibodies being overlooked. In addition, we provide a comprehensive review of all patients with CV2/CRMP5-Ab and NMO-like disease published in the English literature so far. SN - 1872-6968 UR - https://www.unboundmedicine.com/medline/citation/22138095/Antibodies_to_CV2/CRMP5_in_neuromyelitis_optica_like_disease:_case_report_and_review_of_the_literature_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0303-8467(11)00366-0 DB - PRIME DP - Unbound Medicine ER -